The Health Knowledge Garden · Longevity

The Health Knowledge Garden's longevity arm is not a bet on a molecule, a clock, or a founder. It is a bet on a scarcer thing: verified, conflict-free ground truth in a field that runs almost entirely on self-reported, founder- conflicted, over-hyped claims. Longevity is where the meta-crisis lever and the money are both in plain sight — aging is the single largest upstream driver of chronic disease, and the capital chasing "cures" is enormous — but the signal-to-noise ratio is among the worst of any domain RDKG touches. That combination is exactly the shape of garden this cabinet exists to build.

Verification is the product. The field does not lack molecules, clocks, or claims — it lacks a trusted, RCT-grade, conflict-disclosed answer to "does this actually work." HKG's longevity shelf exists to be that answer: every card here is tiered (verified / signal / hype), sourced to a primary document, dated for freshness, and checked for who profits from the claim before it is filed.

The house rule this garden runs on: peer-reviewed lab science and commercial or founder-branded claims are different objects and must be weighted separately, even when they come from the same person. The clearest teaching case in the cabinet is David Sinclair. His lab produced field- defining, independently published science — partial epigenetic reprogramming reversed vision loss in mice (Nature, 2020) and, as of January 2026, reached the first human clinical trial. That is real, load-bearing biology. In the same period, a Sinclair-affiliated company's "reverses aging in dogs" claim triggered an open scientist revolt and cost him the presidency of the Academy for Health and Lifespan Research. One person, two objects, two different trust tiers — never let the halo of one transfer to the other.

Where the money is. Independent verification and certification of longevity claims is the flagship product, sold as decision-support to clinicians, patients, longevity-clinic operators, and investors. Adjacent to it: validating biological-age clocks and biomarkers (a shared cell with MKG, since clocks are commercialized far ahead of settled validity); supplement provenance and quality verification (the NMN regulatory whiplash — excluded by the FDA in 2022, reversed in 2025 — is the poster case for why label-vs- content trust is worth paying for); and clinical-trial navigation, so patients and clinicians can actually find and assess the reprogramming and senolytic trials now reaching humans. All four monetize the same underlying asset: a standing conflict-of-interest layer that asks "who profits from this claim" before the claim is repeated.

Why this is a meta-crisis lever, not just a market. Aging is the top upstream risk factor for most chronic disease. A trustworthy filter on longevity science is not only a commercial opportunity — it is a public-good correction to a field where hype measurably crowds out patients' and clinicians' ability to make good decisions. Getting the signal right here compounds outward into healthspan at population scale.

Guardrail, stated plainly (P0): this garden is internal-first. Nothing in HKG's longevity arm diverts engineering attention from the BKG paywall and first-paying-customer work — that remains the company's P0. Any verification tool, claims feed, or clock-validation service that comes out of this garden starts its life as a spec or a stub, not a build commitment. The garden's job right now is to produce verified cards and hand them to John Bou; the tooling question comes after the smallest experiment answers whether the cards themselves are decision-useful.